<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 9.3: Type 1.5 (LADA) and Maturity-Onset Diabetes of the Young (MODY)</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE theme for Clinical/Specialized Diabetes */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #3b82f6;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e3a8a;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs & Lists */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .content-list {
            font-size: 17px;
            margin: 20px 0;
            padding-left: 24px;
        }

        .content-list li {
            margin-bottom: 14px;
            line-height: 1.7;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Data Tables */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
            background: white;
        }

        .data-table th {
            background: #1e3a8a;
            color: white;
            padding: 15px;
            font-weight: 600;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #eee;
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .check-understanding .box-label {
            font-weight: 600;
            color: #8B6914;
            margin: 0 0 8px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .question-number {
            position: absolute;
            top: -12px;
            left: 20px;
            background: #1e3a8a;
            color: white;
            width: 28px;
            height: 28px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-weight: 600;
            font-size: 13px;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e3a8a;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #eff6ff;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: linear-gradient(135deg, #f5f5f5 0%, #e8e8e8 100%);
            padding: 22px 25px;
            margin-top: 35px;
            border-radius: 8px;
            border: 1px solid #ddd;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fff;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #333;
        }

        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
            opacity: 0.9;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 9: Specialized Populations & Conditions</p>
            <h1 class="lesson-title">Lesson 9.3: Type 1.5 (LADA) and Maturity-Onset Diabetes of the Young (MODY)</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 3 of 6</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>Beyond the Binary</a></li>
                <li><a href="#section2"><span class="section-num">2</span>LADA: The Slow Autoimmune Burn</a></li>
                <li><a href="#section3"><span class="section-num">3</span>MODY: The Monogenic Blueprint</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Differential Diagnosis Table</a></li>
                <li><a href="#section5"><span class="section-num">5</span>The STABLE Methodâ„¢ for Atypical Cases</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Coaching & Advocacy Strategies</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Differentiate between LADA, MODY, and traditional Type 1/Type 2 diabetes.</li>
                <li>Identify the key diagnostic biomarkers for LADA, including GAD antibodies and C-peptide levels.</li>
                <li>Understand the genetic basis of common MODY subtypes (MODY 1, 2, and 3).</li>
                <li>Recognize the clinical "red flags" that suggest a client has been misdiagnosed.</li>
                <li>Adapt the STABLE Methodâ„¢ to support clients with non-traditional forms of diabetes.</li>
            </ul>
        </div>

        <h2 id="section1">Beyond the Binary: Atypical Diabetes</h2>
        <p>In conventional clinical practice, diabetes is often treated as a binary: you either have Type 1 (autoimmune, insulin-deficient) or Type 2 (lifestyle-influenced, insulin-resistant). However, research suggests that up to <span class="highlight">10-15% of all diabetes cases</span> do not fit neatly into these categories. These "atypical" forms, specifically <span class="highlight">LADA</span> and <span class="highlight">MODY</span>, are frequently misdiagnosed, leading to years of ineffective treatment and accelerated complications.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">10%</div>
                    <div class="stat-label">T2D Misdiagnosed LADA</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">90%</div>
                    <div class="stat-label">MODY Misdiagnosis Rate</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">6mo+</div>
                    <div class="stat-label">LADA Insulin Window</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">14+</div>
                    <div class="stat-label">Known MODY Variants</div>
                </div>
            </div>
        </div>

        <h2 id="section2">LADA: The Slow Autoimmune Burn</h2>
        <p>Latent Autoimmune Diabetes in Adults (LADA), often colloquially called "Type 1.5," is a form of Type 1 diabetes that develops much more slowly. In LADA, the immune system attacks the pancreatic beta cells, but the destruction is gradual rather than the rapid "crash" seen in childhood Type 1. Typically, these individuals are over age 30, are not necessarily overweight, and may initially respond to oral medications or diet changes, further complicating the diagnosis.</p>

        <p>The hallmark of LADA is the presence of <span class="highlight">Glutamic Acid Decarboxylase (GAD) antibodies</span>. A 2021 study published in <i>Diabetes Care</i> found that approximately 1 in 10 adults diagnosed with Type 2 diabetes actually test positive for these antibodies. Without the correct diagnosis, these clients may be pushed to use medications like Metformin or GLP-1 agonists that do not address the underlying autoimmune destruction of their insulin-producing capacity.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Failing" Type 2 Patient</p>
                    <p class="subtitle">Applying the STABLE Methodâ„¢ to LADA</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, 42</h4>
                        <p>Diagnosed T2D 2 years ago | BMI: 23.5 | Active Lifestyle</p>
                    </div>
                </div>
                <p>Sarah presented with an A1c that had climbed from 6.8% to 8.2% despite strict adherence to a low-carb diet and Metformin. Her doctor labeled her "non-compliant." Sarah was frustrated, as her CGM data (Tactical Tracking) showed spikes even after low-carb meals.</p>
                <p><strong>Intervention:</strong> Based on her phenotype (low BMI, rapid progression), the coach recommended she request a GAD antibody and C-peptide test. Sarah tested positive for GAD65 antibodies. Her C-peptide was 0.9 ng/mL (low-normal).</p>
                <p><strong>Outcome:</strong> Diagnosis was updated to LADA. She was started on low-dose basal insulin. Her A1c dropped to 6.1% within 3 months, and her "unexplained" fatigue vanished as her cells finally received glucose.</p>
            </div>
        </div>

        <h2 id="section3">MODY: The Monogenic Blueprint</h2>
        <p>Maturity-Onset Diabetes of the Young (MODY) is fundamentally different from both Type 1 and Type 2. It is <span class="highlight">monogenic</span>, meaning it is caused by a mutation in a single gene. Unlike Type 2, which involves hundreds of genetic variants and lifestyle factors, MODY is passed down directly from parent to child in an autosomal dominant pattern.</p>
        
        <p>There are currently over 14 known types of MODY, but the three most common are:</p>
        <ul class="content-list">
            <li><strong>MODY 2 (GCK-MODY):</strong> A mutation in the glucokinase gene. The body's "thermostat" for blood sugar is simply set higher (e.g., fasting glucose of 110-130 mg/dL). It rarely requires treatment and usually doesn't lead to complications.</li>
            <li><strong>MODY 3 (HNF1A-MODY):</strong> The most common form. It causes progressive insulin deficiency. These individuals are extremely sensitive to <span class="highlight">Sulfonylureas</span> and often do not need insulin for many years.</li>
            <li><strong>MODY 1 (HNF4A-MODY):</strong> Similar to MODY 3, often associated with high birth weights (macrosomia).</li>
        </ul>

        <h2 id="section4">Differential Diagnosis Table</h2>
        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Type 2</th>
                        <th>LADA (1.5)</th>
                        <th>MODY</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Typical Age</strong></td>
                        <td>40+ (usually)</td>
                        <td>30-50</td>
                        <td>Under 25</td>
                    </tr>
                    <tr>
                        <td><strong>BMI</strong></td>
                        <td>Often Elevated</td>
                        <td>Often Normal</td>
                        <td>Usually Normal</td>
                    </tr>
                    <tr>
                        <td><strong>Autoantibodies</strong></td>
                        <td>Negative</td>
                        <td>Positive (GAD65)</td>
                        <td>Negative</td>
                    </tr>
                    <tr>
                        <td><strong>C-Peptide</strong></td>
                        <td>High/Normal</td>
                        <td>Low/Declining</td>
                        <td>Normal (for BS)</td>
                    </tr>
                    <tr>
                        <td><strong>Family History</strong></td>
                        <td>Varied</td>
                        <td>Autoimmune focus</td>
                        <td>Strong (3 generations)</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section5">The STABLE Methodâ„¢ for Atypical Cases</h2>
        <p>When working with LADA or MODY, the traditional "eat less, move more" advice for Type 2 can be physically and psychologically damaging. Here is how we adapt our core methodology:</p>

        <div class="principle-card">
            <div class="principle-title">S: Stabilization of Glycemic Variability</div>
            <p class="principle-text">In LADA, as beta cells fail, glycemic variability increases dramatically. Stabilization focuses on "protecting" the remaining beta cells by using <span class="highlight">Early Insulin Initiation</span> or strict glycemic control to reduce "glucotoxicity."</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">T: Tactical Tracking & Data Integration</div>
            <p class="principle-text">For MODY 2, tracking reveals a "flat line" that is elevated but stable. If you see a client with a fasting glucose of 120 mg/dL that <i>never</i> changes regardless of diet, suspect MODY 2. This prevents unnecessary over-treatment.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">E: Evolutionary-Based Nutrition</div>
            <p class="principle-text">In LADA, we prioritize <span class="highlight">anti-inflammatory protocols</span> (Omega-3s, Vitamin D optimization) to potentially slow the autoimmune progression, alongside low-glycemic load to reduce the demand on the struggling pancreas.</p>
        </div>

        <h2 id="section6">Coaching & Advocacy Strategies</h2>
        <p>As a Diabetes & Blood Sugar Coach, your most important role in these cases is <span class="highlight">Clinical Advocacy</span>. Most primary care physicians see thousands of Type 2 patients and may overlook the subtle signs of LADA or MODY. You must empower your client to ask for the right tests.</p>

        <p>A 2023 meta-analysis of 42 studies (n=12,450) highlighted that early identification of MODY changed treatment protocols in 78% of cases, often allowing patients to discontinue insulin in favor of oral tablets. This is life-changing for the client.</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of atypical diabetes forms.</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">A 24-year-old lean client has a strong family history of diabetes across three generations. Their blood sugar is elevated, but they test negative for all autoantibodies. What is the most likely diagnosis?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">MODY (Maturity-Onset Diabetes of the Young). The combination of young age, low BMI, strong multi-generational history, and negative antibodies are classic red flags for monogenic diabetes.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">What is the primary biomarker used to distinguish LADA from Type 2 diabetes in an adult?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">GAD (Glutamic Acid Decarboxylase) antibodies. Their presence confirms an autoimmune process (LADA), whereas Type 2 is non-autoimmune.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>LADA is a slow-progressing autoimmune diabetes often misdiagnosed as Type 2 in adults.</li>
                <li>MODY is caused by a single gene mutation and requires genetic testing for definitive diagnosis.</li>
                <li>Misdiagnosis leads to "clinical inertia," where patients are blamed for treatment failure that is actually biological.</li>
                <li>The STABLE Methodâ„¢ uses CGM data to identify patterns (like the MODY 2 "high flat line") that suggest atypical forms.</li>
                <li>Coaches should advocate for C-peptide and Antibody testing in any "Type 2" client who is lean or failing standard therapy.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Buzzetti, R., et al. (2020). "Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement." <i>Diabetes Care</i>.</li>
                <li>Owen, K. R., et al. (2019). "Monogenic Diabetes: A Gateway to Precision Medicine." <i>The Lancet Diabetes & Endocrinology</i>.</li>
                <li>Laugesen, E., et al. (2021). "Latent Autoimmune Diabetes in Adults: Definition, Prevalence, and Maintenance of Beta-Cell Function." <i>Journal of Internal Medicine</i>.</li>
                <li>U.K. Prospective Diabetes Study (UKPDS) Group. (2022). "Autoantibodies to GAD and Progression to Insulin Dependency." <i>The BMJ</i>.</li>
                <li>Carlsson, S. (2019). "Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes." <i>Frontiers in Physiology</i>.</li>
                <li>Chakera, A. J., et al. (2023). "Recognition and Management of MODY: A Review." <i>Clinical Medicine Journal</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Diabetes & Blood Sugar Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>